@article {722,
	title = {Schuurs{\textendash}Hoeijmakers Syndrome (PACS1 Neurodevelopmental Disorder): Seven Novel Patients and a Review},
	journal = {Genes},
	volume = {12},
	year = {2021},
	month = {Jan-05-2021},
	pages = {738},
	doi = {10.3390/genes12050738},
	url = {https://www.mdpi.com/2073-4425/12/5/738https://www.mdpi.com/2073-4425/12/5/738/pdf},
	author = {Tenorio-Casta{\~n}o, Jair and Morte, Beatriz and Nevado, Juli{\'a}n and Mart{\'\i}nez-Glez, V{\'\i}ctor and Santos-Simarro, Fernando and Garc{\'\i}a-Mi{\~n}aur, Sixto and Palomares-Bralo, Mar{\'\i}a and Pacio-M{\'\i}guez, Marta and G{\'o}mez, Beatriz and Arias, Pedro and Alcochea, Alba and Carri{\'o}n, Juan and Arias, Patricia and Almoguera, Berta and L{\'o}pez-Grondona, Fermina and Lorda-Sanchez, Isabel and Gal{\'a}n-G{\'o}mez, Enrique and Valenzuela, Irene and M{\'e}ndez Perez, Mar{\'\i}a and Cusc{\'o}, Iv{\'o}n and Barros, Francisco and Pi{\'e}, Juan and Ramos, Sergio and Ramos, Feliciano and Kuechler, Alma and Tizzano, Eduardo and Ayuso, Carmen and Kaiser, Frank and P{\'e}rez-Jurado, Luis and Carracedo, {\'A}ngel and Lapunzina, Pablo}
}
@article {1083,
	title = {A New Overgrowth Syndrome is Due to Mutations in RNF125.},
	journal = {Human mutation},
	volume = {35},
	year = {2014},
	month = {2014 Sep 5},
	pages = {1436{\textendash}1441},
	abstract = {Overgrowth syndromes (OGS) are a group of disorders in which all parameters of growth and physical development are above the mean for age and sex. We evaluated a series of 270 families from the Spanish Overgrowth Syndrome Registry with no known overgrowth syndrome. We identified one de novo deletion and three missense mutations in RNF125 in six patients from 4 families with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycaemia and inflammatory diseases resembling Sj{\"o}gren syndrome. RNF125 encodes an E3 ubiquitin ligase and is a novel gene of OGS. Our studies of the RNF125 pathway point to upregulation of RIG-I-IPS1-MDA5 and/or disruption of the PI3K-AKT and interferon signaling pathways as the putative final effectors. This article is protected by copyright. All rights reserved.},
	keywords = {NGS, prioritization, Rare Disease},
	issn = {1098-1004},
	doi = {10.1002/humu.22689},
	url = {http://onlinelibrary.wiley.com/doi/10.1002/humu.22689/abstract},
	author = {Tenorio, Jair and Mansilla, Alicia and Valencia, Mar{\'\i}a and Mart{\'\i}nez-Glez, V{\'\i}ctor and Romanelli, Valeria and Arias, Pedro and Castrej{\'o}n, Nerea and Poletta, Fernando and Guill{\'e}n-Navarro, Encarna and Gordo, Gema and Mansilla, Elena and Garc{\'\i}a-Santiago, F{\'e} and Gonz{\'a}lez-Casado, Isabel and Vallesp{\'\i}n, Elena and Palomares, Mar{\'\i}a and Mori, Mar{\'\i}a A and Santos-Simarro, Fernando and Garc{\'\i}a-Mi{\~n}aur, Sixto and Fern{\'a}ndez, Luis and Mena, Roc{\'\i}o and Benito-Sanz, Sara and Del Pozo, Angela and Silla, Juan Carlos and Iba{\~n}ez, Kristina and L{\'o}pez-Granados, Eduardo and Mart{\'\i}n-Trujillo, Alex and Montaner, David and Heath, Karen E and Campos-Barros, Angel and Joaqu{\'\i}n Dopazo and Nevado, Juli{\'a}n and Monk, David and Ruiz-P{\'e}rez, V{\'\i}ctor L and Lapunzina, Pablo}
}
